Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Birla Carbon (Thailand) Public Company Limited (BCT.BK)
Bangkok, TH
Birla Carbon (Thailand) Public Company Limited specializes in the manufacturing and worldwide distribution of carbon black, a crucial substance utilized in rubber products and diverse specialized sectors. Its offerings are commercialized under the recognizable Birla Carbon brand. The company's operations extend across numerous nations, including Thailand, Japan, Indonesia, Vietnam, and Malaysia, alongside a broader international footprint. Formerly designated as Thai Carbon Black Public Company Limited, the firm adopted its current name, Birla Carbon (Thailand) Public Company Limited, in July 2018. Established in 1978, its primary office is situated in Bangkok, Thailand.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +4.17% | -0.99% | -3.85% | -2.91% | +5.82% | -10.71% | +5.82% | +118.34% | +681.25% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Chemicals - Specialty: +4.7%-20.4% Q1'26: -16.5% (vs Q1'25)
-
EPS growth Chemicals - Specialty: +13.2%-25.0% Q1'26: +14.8% (vs Q1'25)
-
FCF margin FCF growth · Chemicals - Specialty: +44.1%+6.6% Q1'26: -59.7% (vs Q1'25)
-
EBIT margin Chemicals - Specialty: +8.8%+10.7% ★ Q1'26: +6.5% (vs Q1'25)
-
ROIC Chemicals - Specialty: +5.6%+2.8% Q1'26: +1.7% (vs Q1'25)
-
Share dilution Chemicals - Specialty: +0.1%+0.0% Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Chemicals - Specialty: 0.18×0.00× ★ Q1'26: 0.00× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A | 4/5 | 3/5 | 3/5 | 5/5 | 4/5 | 3/5 | 5/5 |
| 2026-05-28 | A | 4/5 | 3/5 | 3/5 | 5/5 | 4/5 | 3/5 | 5/5 |
| 2026-05-27 | A | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-26 | A | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-20 | A | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-19 | A | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-18 | A | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-15 | A | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-14 | A | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-13 | A | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-12 | A | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-11 | A | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-08 | A | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-07 | A | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-06 | A | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-05 | A | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-30 | A | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-29 | A | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-28 | A | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-27 | A | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-24 | A | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-23 | A | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-22 | A | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-21 | A | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-20 | A | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-17 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-16 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Sanjeev Sood | President & Director | 100.0K | male |
| Atikan Pinsuk | Head of Human Resources | — | female |
| Jayant Gehlot | Head of Marketing | — | male |
| Laurent Kosbach | Chief Executive Officer of Nanocyl | — | — |
| Amit Gupta | Head of Manufacturing | — | male |
| Rajendra Vijay | Chief Financial Officer and Head of Finance & Accounts | — | male |
| Sandeep Kumar | Head of Supply Chain | — | male |
| Sanjay Sharma | Unit Head | — | male |
| Orawan Rakangsomboon | Company Secretary | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for BCT.BK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
